Predicting novel drugs for SARS-CoV-2 using machine learning from a >10 million chemical space
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
There is an urgent need for the identification of effective therapeutics for COVID-19 and we have developed a machine learning drug discovery pipeline to identify several drug candidates. First, we collect assay data for 65 target human proteins known to interact with the SARS-CoV-2 proteins, including the ACE2 receptor. Next, we train machine learning models to predict inhibitory activity and use them to screen FDA registered chemicals and approved drugs (~100,000) and ~14 million purchasable chemicals. We filter predictions according to estimated mammalian toxicity and vapor pressure. Prospective volatile candidates are proposed as novel inhaled therapeutics since the nasal cavity and respiratory tracts are early bottlenecks for infection. We also identify candidates that act across multiple targets as promising for future analyses. We anticipate that this theoretical study can accelerate testing of two categories of therapeutics: repurposed drugs suited for short-term approval, and novel efficacious drugs suitable for a long-term follow up.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DrugBank 5.0: a major update to the DrugBank database for 2018
Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1037 · Cited by 8,404 · cited 1×
“Accordingly, we used the machine learning models to predict activities of ~100,000 FDA registered chemicals (UNII database) [19] as well as the DrugBank [20] and Therapeutic Targets [21, 22] databases, which include information on drug interactions, pathways, and approval status.”
MethodA SARS-CoV-2 protein interaction map reveals targets for drug repurposing
Gordon, D. E., Jang, G. M., Bouhaddou, M., Xu, J., Obernier, K., White, K. M., O’Meara, M. J., Rezelj, V. V., Guo, J. Z., Swaney, D. L., et al. (2020) · Nature · doi:10.1038/s41586-020-2286-9 · Cited by 4,405
Wan, Y., Shang, J., Graham, R., Baric, R. S., & Li, F. (2020) · Journal of Virology · doi:10.1128/jvi.00127-20 · Cited by 4,341
ZINC 15 – Ligand Discovery for Everyone
Sterling, T., & Irwin, J. J. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00559 · Cited by 3,224 · cited 2×
“There are subsequently unmet needs in COVID-19 research, including identification of compounds that target the relevant SARS-CoV-2 human proteins from (1) approved drugs, (2) FDA registered chemicals or (3) a large repository of ~14 million purchasable chemicals from the ZINC 15 database [18], which we computed additi…”
BackgroundHCA Lung Biological Network, Sungnak, W., Huang, N., Bécavin, C., Berg, M., Queen, R., Litvinukova, M., Talavera-López, C., Maatz, H., Reichart, D., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0868-6 · Cited by 2,501
ChEMBL: towards direct deposition of bioassay data
Mendez, D., Gaulton, A., Bento, A. P., Chambers, J., De Veij, M., Félix, E., Magariños, M. P., Mosquera, J. F., Mutowo, P., Nowotka, M., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1075 · Cited by 2,372
Li, Y., Bai, W., & Hashikawa, T. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25728 · Cited by 2,266
High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2
Sanche, S., Lin, Y. T., Xu, C., Romero-Severson, E., Hengartner, N., & Ke, R. (2020) · Emerging Infectious Diseases · doi:10.3201/eid2607.200282 · Cited by 1,619 · cited 1×
“The SARS-CoV-2 also produces similarly severe respiratory conditions, albeit at a lower rate but with a higher contagion factor [1].”
BackgroundSantosh, K. C. (2020) · Journal of Medical Systems · doi:10.1007/s10916-020-01562-1 · Cited by 341
Coincidence of COVID-19 epidemic and olfactory dysfunction outbreak
Bagheri, S. H., Asghari, A., Farhadi, M., Shamshiri, A. R., Kabir, A., Kamrava, S. K., Jalessi, M., Mohebbi, A., Alizadeh, R., Honarmand, A. A., et al. (2020) · doi:10.1101/2020.03.23.20041889 · Cited by 179
Cited by
Machine Learning Methods in Drug Discovery
Patel, L., Shukla, T., Huang, X., Ussery, D. W., & Wang, S. (2020) · Molecules · doi:10.3390/molecules25225277 · Cited by 460
Artificial Intelligence Technologies for COVID-19 De Novo Drug Design
Floresta, G., Zagni, C., Gentile, D., Patamia, V., & Rescifina, A. (2022) · doi:10.20944/preprints202203.0032.v1 · Cited by 67
Current State and Prospects of Artificial Intelligence in Allergy
van Breugel, M., Fehrmann, R. S. N., Bügel, M., Rezwan, F. I., Holloway, J. W., Nawijn, M. C., Fontanella, S., Custovic, A., & Koppelman, G. H. (2023) · Allergy · doi:10.1111/all.15849 · Cited by 43
Metadata
- Authors
- Kowalewski, J., & Ray, A.
- Venue
- Heliyon
- Publisher
- Elsevier BV
- Published
- 2020-08
- Volume
- 6
- Issue
- 8
- Pages
- e04639
- ISSN
- 2405-8440 (ISSN-L)
- OpenAlex
- W3047072418
- Cited by
- 76
- References
- 10
- FWCI
- 7.50
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Predicting novel drugs for SARS-CoV-2 using machine learning from a >10 million chemical space. https://app.cochat.ai/papers/10.1016/j.heliyon.2020.e04639
- The paper
- Kowalewski, J., & Ray, A. (2020). Predicting novel drugs for SARS-CoV-2 using machine learning from a >10 million chemical space. Heliyon. https://doi.org/10.1016/j.heliyon.2020.e04639
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.